150 related articles for article (PubMed ID: 26461012)
1. External Beam Radiation Therapy and Abiraterone in Men With Localized Prostate Cancer: Safety and Effect on Tissue Androgens. In Regard to Cho et al.
Bhattacharyya T; Purushothaman K; Puthiyottil SS; Muttath G
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):719. PubMed ID: 26461012
[No Abstract] [Full Text] [Related]
2. External beam radiation therapy and abiraterone in men with localized prostate cancer: safety and effect on tissue androgens.
Cho E; Mostaghel EA; Russell KJ; Liao JJ; Konodi MA; Kurland BF; Marck BT; Matsumoto AM; Dalkin BL; Montgomery RB
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):236-43. PubMed ID: 25772183
[TBL] [Abstract][Full Text] [Related]
3. In Reply to Bhattacharyya et al.
Cho E; Mostaghel EA; Russell KJ; Liao JJ; Montgomery B
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):719-20. PubMed ID: 26461011
[No Abstract] [Full Text] [Related]
4. Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease.
D'Amico AV; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; Chen MH
J Clin Oncol; 2009 Aug; 27(24):3923-8. PubMed ID: 19597029
[TBL] [Abstract][Full Text] [Related]
5. External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation.
Koontz BF; Lee WR
Arch Esp Urol; 2011 Oct; 64(8):858-64. PubMed ID: 22052767
[TBL] [Abstract][Full Text] [Related]
6. In Regard to Bauman et al.
Kishan AU; Steinberg ML; Kupelian PA; King CR
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1162-3. PubMed ID: 26581152
[No Abstract] [Full Text] [Related]
7. Risk-based management of prostate cancer.
D'Amico AV
N Engl J Med; 2011 Jul; 365(2):169-71. PubMed ID: 21751910
[No Abstract] [Full Text] [Related]
8. Prostate-specific antigen halving time while on neoadjuvant androgen deprivation therapy is associated with biochemical control in men treated with radiation therapy for localized prostate cancer.
Malik R; Jani AB; Liauw SL
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1022-8. PubMed ID: 20510547
[TBL] [Abstract][Full Text] [Related]
9. First-line abiraterone improves survival in prostate cancer.
Brower V
Lancet Oncol; 2017 Jul; 18(7):e374. PubMed ID: 28602778
[No Abstract] [Full Text] [Related]
10. [High risk prostate cancer results of one year RT-HT].
Delaporte V; Muracciole X; Lechevalier E; Bastide C; Cowen D; Rossi D; Coulange C
Prog Urol; 2005 Dec; 15(6 Suppl 1):1256-61. PubMed ID: 16734214
[No Abstract] [Full Text] [Related]
11. The importance of combined radiation and endocrine therapy in locally advanced prostate cancer.
Gray PJ; Shipley WU
Asian J Androl; 2012 Mar; 14(2):245-6. PubMed ID: 22198629
[No Abstract] [Full Text] [Related]
12. Nonsteroidal anti-androgens: role in treating advanced prostate cancer.
Newton M; Kosier JH
Urol Nurs; 1998 Mar; 18(1):56-7, 83. PubMed ID: 9582897
[No Abstract] [Full Text] [Related]
13. In Reply to Kishan et al.
Bauman G; Rodrigues G; Chen J; Loblaw A
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1163. PubMed ID: 26581153
[No Abstract] [Full Text] [Related]
14. Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question!
Messina C; Messina M; Boccardo F
Eur Urol; 2018 Jan; 73(1):147-148. PubMed ID: 28801126
[No Abstract] [Full Text] [Related]
15. Androgen deprivation therapy for prostate cancer.
Bahnson R
J Urol; 2007 Oct; 178(4 Pt 1):1148. PubMed ID: 17698142
[No Abstract] [Full Text] [Related]
16. Endocrine therapy of prostate cancer: optimal form and timing.
Labrie F
J Clin Endocrinol Metab; 1995 Apr; 80(4):1066-71. PubMed ID: 7714068
[No Abstract] [Full Text] [Related]
17. STAMPEDE: Is Radiation Therapy to the Primary a New Standard of Care in Men with Metastatic Prostate Cancer?
Choudhury A; Chen RC; Henry A; Mistry H; Mitin T; Pinkawa M; Spratt DE
Int J Radiat Oncol Biol Phys; 2019 May; 104(1):33-35. PubMed ID: 30967237
[No Abstract] [Full Text] [Related]
18. Prostate cancer. Introduction.
Crawford ED
Urology; 2003 Dec; 62(6 Suppl 1):1-2. PubMed ID: 14706502
[No Abstract] [Full Text] [Related]
19. Prostate cancer: Effectiveness of abiraterone is unaffected by prior ADT.
Sidaway P
Nat Rev Urol; 2016 Jan; 13(1):2. PubMed ID: 26553628
[No Abstract] [Full Text] [Related]
20. [Androgen deprivation plus abiraterone/prednisone in metastatic hormone-sensitive prostate cancer : Joint statement by the Study Group on Oncology (AKO) and the Working Group on Urological Oncology (AUO)].
Ohlmann CH; Miller K; Gschwend J
Urologe A; 2017 Sep; 56(9):1185-1186. PubMed ID: 28733874
[No Abstract] [Full Text] [Related]
[Next] [New Search]
